We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App





Huge COVID-19 Testing Demand to Drive Global Point-of-Care Diagnostics Market to USD 11.7 Billion by 2024

By LabMedica International staff writers
Posted on 01 Oct 2020
Print article
Illustration
Illustration
The global point-of-care diagnostics market stood at USD 6.8 billion in 2016 and is expected to register a stellar CAGR of 6.9% to reach USD 11.7 billion by the end of 2024, driven mainly by the rise in COVID-19 testing. Other factors supporting the growth of the point-of-care diagnostics market are the increased prevalence of infectious diseases such as tuberculosis, AIDS, etc. and the rising incidences of target conditions. The increasing demand for rapid diagnostics among the general populace is also assisting the growth of the point-of-care diagnostics market.

These are the latest findings of Transparency Market Research (Albany NY, USA), a market research company.

The need for making the healthcare sector more patient-centric is proving to be beneficial for the increase in the growth rate of the point-of-care diagnostics market. The centralized testing process does not seem convenient for many patients as it involves frequent visits to the clinics to complete the entire assessment process. Point-of-care devices offer a much-needed helping hand for achieving the goal of a patient-centric approach. As a result, the point-of-care diagnostics market is likely to experience a considerable spike in its growth rate during the forecast period.

The COVID-19 outbreak has prompted a fierce demand for point-of-care diagnostics kits. As of now, no vaccine is available for controlling the deadly disease. Maximum testing and quick hospitalization are key components for flattening the curve. The point-of-care diagnostics devices form the crux of increased testing. Manufacturers in the point-of-care diagnostics market are focusing on developing novel technologies for maximum testing within a minimum period. The use of cutting-edge technologies enables the point-of-care diagnostic kits to target RdRp genes for detecting positive cases in as little as five minutes. CRISPR-based technologies are also helping generate growth for the point-of-care diagnostics market to a great extent. The novel coronavirus has accelerated research and development activities in the point-of-care diagnostics market. Development and production in maximum numbers is the need of the hour. Therefore, quick FDA approvals are fueling the growth of the point-of-care diagnostics market.

Given the rising threat of SARS-CoV-2 transmission, the influx of patients to the clinics is likely to decline significantly. Thus, home care may gain considerable traction even after the lockdown. Eventually, smartphone-based point-of-care diagnostics is estimated to propel the market growth. Innovations such as smartphones combined with a microfluidic chip for rapid testing results could generate tremendous growth opportunities for the point-of-care diagnostics market. Home-based glucose monitoring systems are also garnering good sales due to the launch of innovative and advanced monitoring technologies such as well as the frequent multiplication of diabetes cases across the world. Also, patients with co-morbidities are more prone to fatality caused due to COVID-19. Hence, these devices provide efficient diagnostics at home without feeling the need for a visit to the clinic for consultation.

The major players are betting heavily on the growth of the point-of-care diagnostics market through investments, mergers, acquisitions, joint ventures, and partnerships. An increase in medical and surgical procedures, coupled with the advancement of new technologies, makes the point-of-care diagnostics market a profitable option for investment. The soaring demand for point-of-care diagnostics is likely to boost the scale of investments in the market. Major players involved in the point-of-care diagnostics market are always engaged in discovering efficient and path-breaking products. Further, the adoption of various technologies such as ultrasounds can also aid the growth of the point-of-care diagnostics market.

Geographically, North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America are the major regional segments of the global point-of-care diagnostics market. North America will continue to lead the global point-of-care diagnostics market due to early access to the availability of new technologies and advanced healthcare infrastructure in the region. Rising cases of diabetes in the US is likely to support the growth of the North American point-of-care diagnostics market. Additionally, mini-growth enhancers such as technology miniaturization, improved portability, and lower system cost will further benefit the point-of-care diagnostics market in North America.

Related Links:
Transparency Market Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.